USPTO Examiner CRUM MARY ABOU NADER - Art Unit 1657

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18884680BACTERIAL COMPOSITIONS FOR TREATING AND PREVENTING HALITOSISSeptember 2024November 2025Allow1421NoNo
18627183PROBIOTIC COMPOSITIONS FOR TREATING AND PREVENTING COLORECTAL CANCERApril 2024February 2026Allow2231YesNo
17909760BACILLUS VELEZENSIS STRAIN BRED THROUGH ULTRASOUND-ASSISTED ADAPTIVE EVOLUTION, AND USE THEREOFFebruary 2023January 2025Abandon2801NoNo
18152641NOVEL STREPTOCOCCUS THERMOPHILUS STRAIN AND PROBIOTIC COMPOSITION AND USE THEREOFJanuary 2023June 2025Abandon2931YesNo
18147722LACTOBACILLUS SAKEI AND METHOD FOR EYE PROTECTION WITH LACTOBACILLUS SAKEI OR METABOLITE THEREOFDecember 2022May 2024Abandon1710NoNo
17927167COMPOSITION FOR TREATING RESPIRATORY DISEASES OR INFLAMMATORY DISEASES CAUSED BY FINE DUST STIMULATION, CONTAINING LACTIC ACID BACTERIANovember 2022March 2026Allow4011YesNo
17985500LACTOBACILLUS SAKEI FOR ALLEVIATING ALLERGY AND PREPARATION METHOD THEREOFNovember 2022February 2024Abandon1511NoNo
17979878METHOD FOR PRODUCING MONOUNSATURATED FATTY ACID HAVING 16 CARBON ATOMSNovember 2022March 2024Abandon1601NoNo
17973449PROBIOTIC COMPOSITIONS FOR LONG COVIDOctober 2022August 2025Allow3461YesNo
17969941COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE AND JOINT DISEASESOctober 2022July 2024Abandon2131NoNo
17968831SELECTIVE MEDIUM COMPOSITION FOR DETECTION OF P. CAROTOVORUM AND DETECTION METHOD USING THE SAMEOctober 2022September 2024Allow2340YesNo
17968161SPORE-BASED PROBIOTIC COMPOSITION FOR REDUCTION OF DIETARY ENDOTOXEMIA AND RELATED METHODSOctober 2022March 2026Abandon4120NoNo
17996501COMPOSITION FOR PREVENTING OR TREATING LIPID-RELATED METABOLIC DISEASES, COMPRISING LACTOBACILLUS PLANTARUM ATG-K2 OR ATG-K6October 2022January 2026Abandon3911NoNo
18045264USE OF DOPAMINE PRODUCING PRODUCTS TO INCREASE VACCINE EFFICACYOctober 2022March 2025Allow2941YesYes
17917385COMPOSITION FOR IMPROVING GUT MICROBIOTAOctober 2022September 2025Allow3511YesNo
17913505MICROORGANISM FOR IMPROVING LIVER FUNCTION OR INHIBITING FAT ACCUMULATION, AND USES OF SAMESeptember 2022August 2025Abandon3501NoNo
17949757COMPOSITION FOR PROPHYLAXIS OF ENTERITIS IN AVIAN COMPRISING LACTOBACILLUS PLANTARUM STRAINSeptember 2022July 2025Allow3421YesNo
17913210LACTOBACILLUS DELBRUECKII SUBSP. LACTIS CKDB001 STRAIN, AND COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER COMPRISING SAMESeptember 2022October 2025Allow3711YesNo
17932427Isolated Strain Of Lactic Acid Bacteria For Inhibiting Drug-Resistant Enterobacteriaceae, Lactic Acid Bacterial Composition And Symbiotic Composition Including The SameSeptember 2022December 2024Abandon2730NoNo
17909141LACTIC ACID BACTERIUM-CONTAINING COMPOSITIONSeptember 2022July 2025Abandon3401NoNo
17895071PROBIOTICS SEPARATED FROM RABBIT FECES AND FOOD CONTAINING PROBIOTICSAugust 2022January 2025Abandon2930YesNo
17893840Novel Lactobacillus Fermentum LM1016 Strain, And Composition For Preventing Or Treating Cardiovascular DiseasesAugust 2022July 2025Abandon3501NoNo
17881498PROBIOTIC COMPOSITIONS FOR TREATING AND PREVENTING COLORECTAL CANCERAugust 2022January 2024Allow1731YesYes
17815447METHOD FOR PREPARING R-HYDROXYNITRILE LYASE AND USE THEREOFJuly 2022November 2023Allow1611YesNo
17866911METHODS FOR MANUFACTURING ANGELICA GIGAS NAKAI EXTRACT USING FERMENTATION BACTERIAJuly 2022March 2024Abandon2020NoNo
17792585Bacterium, Composition and Method for Producing Same, and Prebiotics CompositionJuly 2022March 2026Allow4421YesNo
17792329METHODS FOR TREATING OR AMELIORATING AUTISM AND RELATED DISORDERSJuly 2022January 2026Abandon4311NoNo
17824452ATTENUATED SALMONELLA GALLINARUM MUTANT STRAINS AND USES THEREOFMay 2022November 2024Abandon3040NoNo
17824608ATTENUATED SALMONELLA GALLINARUM MUTANT STRAINS AND USES THEREOFMay 2022November 2024Abandon3040NoNo
17741951PROCESS FOR THE PREPARATION OF ANTIMALASSEZIA POWDERMay 2022November 2025Allow4230YesNo
17726481VACCINATION AGAINST FUNGAL EPITOPES TO PREVENT INFLAMMATORY BOWEL DISEASESApril 2022April 2024Abandon2420NoNo
17657902BIOCONVERSION OF METHANE TO 3-HYDROXYBUTYRATEApril 2022March 2024Abandon2320NoNo
17711430ENGINEERED CYCLIC GMP-AMP SYNTHASE (cGAS) VARIANT ENZYMESApril 2022August 2024Allow2931YesNo
17691075CONVERSION OF LIGNIN-DERIVED MONOMERS TO MUCONATE BY ENGINEERED PSEUDOMONASMarch 2022March 2026Allow4860YesNo
17635942THERAPEUTIC CONJUGATEFebruary 2022June 2025Abandon4011NoNo
17634074BACTERIAL COMPOSITIONS FOR THE TREATMENT OF DISEASEFebruary 2022June 2025Abandon4011NoNo
17575460RECOMBINANT MICROORGANISM HAVING HIGH ABILITY TO PRODUCE LUTEIN AND METHOD FOR PRODUCING LUTEIN USING THE SAMEJanuary 2022January 2026Abandon4861NoNo
17564567EDIBLE WEB COMPRISING MICROORGANISMSDecember 2021November 2025Abandon4720NoNo
17551271OLEAGINOUS MICROBE SUPPLEMENTATION FOR IMPROVING BLACK SOLDIER FLY GROWTH AND DEVELOPMENTDecember 2021July 2025Abandon4351NoNo
17549692Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsDecember 2021February 2025Abandon3941NoNo
17547845DIAGNOSING HEART DISEASE AND DEGENERATIVE MITRAL VALVE DISEASE IN A CANINEDecember 2021November 2025Abandon4751NoYes
17536412Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application ThereofNovember 2021July 2025Allow4421YesNo
17611240STRAIN SHOWING LIVER FUNCTION IMPROVING ACTIVITY, AND USE THEREOFNovember 2021November 2025Abandon4821NoNo
17609975DEPOLYMERASE CAPABLE OF DEGRADING EXTRACELLULAR POLYMERIC SUBSTANCES OF KLEBSIELLA PNEUMONIAENovember 2021June 2025Allow4321YesNo
17519595PREBIOTIC COMPOSITION AND METHOD FOR IMPROVING INTESTINAL HEALTH USING THE SAMENovember 2021May 2025Allow4260YesNo
17520561MESH-BASED IN SITU CROSS-LINKABLE COMPOSITIONSNovember 2021February 2026Abandon5130YesNo
17608729NOVEL HYALURONIDASE VARIANTS WITH IMPROVED STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAMENovember 2021December 2025Allow5021YesNo
17492367PREDICTING SKIN AGE BASED ON THE ANALYSIS OF SKIN FLORA AND LIFESTYLE DATAOctober 2021December 2024Abandon3901NoNo
17600650NOVEL BIFIDOBACTERIUM LONGUM STRAIN OR COSMETIC COMPOSITION COMPRISING SAMEOctober 2021November 2024Abandon3701NoNo
17600461ELASTASE ACTIVITY INHIBITOR, ELASTASE ACTIVITY INHIBITING TOPICAL AGENT, AND ELASTASE ACTIVITY INHIBITING FOOD AND BEVERAGE COMPOSITIONSeptember 2021January 2025Abandon3910NoNo
17599104BACILLUS COAGULANS AND BACILLUS SUBTILIS FOR THE PREVENTION AND TREATMENT OF FUNCTIONAL GASTRO-INTESTINAL DISORDERSSeptember 2021June 2025Allow4421NoNo
17436021COMBINATIONS OF TANNASE AND PROBIOTIC FORMULATIONS AND METHODS OF USE FOR IMPROVING TANNIN METABOLISMSeptember 2021February 2026Abandon5321NoNo
17432846BACTERIAL MEMBRANE PREPARATIONSAugust 2021November 2024Abandon3901NoNo
17432225COMPOSITIONS AND METHODS OF MODULATING CASOTRANSMITTER SIGNALINGAugust 2021January 2026Abandon5331NoNo
17431040Hemostatic Enzyme and Carboxymethyl Chitosan-Containing Composition for Blood Coagulation Test, and Use ThereofAugust 2021February 2025Abandon4211NoNo
17392975METHODS AND COMPOUNDS FOR NATURAL ORGANIC INTENSIVE SKIN REPAIR AND HEALINGAugust 2021September 2024Abandon3811NoNo
17425080METHODS AND COMPOSITIONS FOR TREATING INTESTINAL DISORDERJuly 2021August 2025Allow4941YesNo
17379605METHODS FOR CHROMATOGRAPHIC PROTEIN EXTRACTION AND PURIFICATIONJuly 2021December 2024Abandon4021NoNo
17422719METHODS AND COMPOSITIONS FOR TREATING IMMUNE CHECKPOINT INHIBITOR ASSOCIATED COLITISJuly 2021January 2026Abandon5441YesNo
17360695METHODS FOR IDENTIFYING TARGETS FOR ANTIMICROBIAL AND ANTIPROLIFERATIVE COMPOUNDS AND COMPOSITIONS THEREFROMJune 2021November 2025Abandon5321NoNo
17279247AKKERMANSIA MUCINIPHILA STRAIN AND USE THEREOFMarch 2021August 2025Allow5231YesNo
17276334IMMUNE CHECKPOINT SUPPRESSANTMarch 2021March 2024Abandon3610NoNo
17181884RECOMBINANT TRANSMEMBRANE DOMAIN-DEFICIENT STING AS BIOMIMETIC PROTEIN CARRIER FOR CGAMP ENHANCED CANCER IMMUNOTHERAPYFebruary 2021March 2024Abandon3702NoNo
17166515METHOD FOR PRODUCING STABLE ACTINIDIA DELICIOSA POWDER WITH HIGH LEVEL BIOACTIVE ACTINIDIN ENZYMEFebruary 2021August 2024Allow4231YesNo
17264722FLUORESCENT-LABELED ANTIBODY OR ANTIBODY FRAGMENTJanuary 2021July 2024Abandon4101NoNo
17258297SELF-ASSEMBLING PEPTIDE SCAFFOLDJanuary 2021July 2025Allow5421YesNo
17254206COMPOSITION FOR IMPROVING LIVER FUNCTION COMPRISING LEUCONOSTOC SP. STRAINDecember 2020January 2024Abandon3701NoNo
17115591PLAP-CAR-EFFECTOR CELLSDecember 2020February 2024Allow3911YesNo
16972741Engineering Extracellular Vesicles for Affinity PurificationDecember 2020June 2024Abandon4201NoNo
17056569RECOMBINANT BOVINE FOLLICLE-STIMULATING HORMONE, COMPOSITION COMPRISING THE SAME, AND METHOD TO INDUCE SUPEROVULATION AND ESTRUS SYNCHRONIZATION IN BOVINES USING SAID HORMONENovember 2020October 2024Abandon4711NoNo
17054089METHOD FOR MEASURING AND IMPROVING GUT HEALTHNovember 2020August 2024Abandon4501NoNo
17050639MODIFIED STEROL ACYLTRANSFERASESOctober 2020January 2026Allow6041YesNo
17049756METHOD FOR PRODUCING COENZYME Q10October 2020April 2025Abandon5320NoNo
17048916COMPOSITION FOR TYPE I ALLERGYOctober 2020December 2023Abandon3810NoNo
17048355Variant Asparaginase Polypeptides for Medical UseOctober 2020January 2025Abandon5121NoNo
17060503BREATH TEST DEVICE AND METHODOctober 2020July 2024Abandon4620NoNo
17042984METHODS OF PURIFYING MONOMERIC MONOCLONAL ANTIBODIESSeptember 2020November 2025Abandon6040NoNo
17019422HARVESTING SYSTEMS AND METHODS FOR REMOVAL OF ALGAE SLURRY IMPURITIESSeptember 2020October 2023Abandon3711NoNo
16980364Magnetic Nanoparticles for use in Assisted ReproductionSeptember 2020September 2024Abandon4811NoNo
17010644Enhanced adoptive cell therapySeptember 2020May 2025Allow5730NoNo
16965743METHOD FOR EFFICIENTLY RECOVERING AND PURIFYING ACTIVE CRM197 FROM INSOLUBLE CRM197 PROTEIN EXPRESSED IN INCLUSION BODYJuly 2020March 2025Abandon5530NoNo
16962793MANUFACTURE OF GLUCAGON PEPTIDESJuly 2020November 2025Allow6031NoNo
16771772AMINOPEPTIDASE AND ITS USESJune 2020December 2024Abandon5431NoNo
16766977A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUISMay 2020January 2024Abandon4420NoNo
16760377NOVEL RECOMBINANT BOTULINUM TOXIN WITH INCREASED DURATION OF EFFECTApril 2020October 2024Abandon5441YesNo
16755129ELASTIN REDUCTION ALLOWING RECELLULARIZATION OF CARTILAGE IMPLANTSApril 2020July 2025Abandon6031NoNo
16632060MANUAL METHOD FOR DEPOSITING A SAMPLE DIRECTLY ONTO A SLIDE FOR LIQUID BASED CYTOLOGYJanuary 2020August 2024Allow5540YesYes
16609146METHOD AND DEVICE FOR PROVIDING A CELL LINE HAVING A DESIRED TARGET PROTEIN EXPRESSIONOctober 2019December 2023Abandon5020NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CRUM, MARY ABOU NADER.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
1
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.9%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
1
(33.3%)
Not Allowed After Appeal Filing
2
(66.7%)
Filing Benefit Percentile
50.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner CRUM, MARY ABOU NADER - Prosecution Strategy Guide

Executive Summary

Examiner CRUM, MARY ABOU NADER works in Art Unit 1657 and has examined 51 patent applications in our dataset. With an allowance rate of 27.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner CRUM, MARY ABOU NADER's allowance rate of 27.5% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CRUM, MARY ABOU NADER receive 2.16 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CRUM, MARY ABOU NADER is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +70.5% benefit to allowance rate for applications examined by CRUM, MARY ABOU NADER. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.8% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.